Back to search results

DSLT for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma

This study is looking at how well a procedure called Direct Selective Laser Trabeculoplasty (DSLT) using the Belkin Vision Eagle Device can lower eye pressure in adults with primary open angle glaucoma (POAG). POAG is an eye condition that can damage your optic nerve and cause vision loss. The study focuses on non-Caucasian patients of Black African descent with mild to moderate POAG. Researchers want to see if DSLT can reduce eye pressure significantly after 6 months, compared to before the procedure. They will also check how many patients no longer need glaucoma medications after 6 months. The study aims to enroll 60 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 60 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo the DSLT procedure in one or both eyes. You would then visit the clinic 1 month, 3 months, and 6 months after the procedure for vision and eye pressure measurements.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 months after the DSLT procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07147647

Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma

Recruiting
NAAges 18+InterventionalTreatment
Select Eye Care
~60 participants
Updated 2025-08-29 on ClinicalTrials.gov
What's tested:Direct Selective Laser Trabeculoplasty

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
IOP reduction at 6 months washed out post-DSLT compared with washed out baseline IOP.
Measured over 6 Months post-DSLT

Conditions

Primary Open Angle Glaucoma (POAG)

Explore related trials

Primary Open Angle Glaucoma

Where it's being run

1 sites across 1 states
Maryland1

Who to contact

Scott E LaBorwit, MD
[email protected]
410-821-6400
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes.
Diagnosis of mild to moderate primary open angle glaucoma (POAG).
Mild to moderate POAG will be defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system.
Treatment naive or washed out IOP at time 0 ranging from ≥ 21 through 32 mm Hg.

Exclusion

Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0).
Previous glaucoma surgeries/interventions:
Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
Secondary glaucoma:
Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.
Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.
Subjects who are pregnant, breast-feeding, or intend to become pregnant during the study period as determined by verbal inquiry.

What this trial measures

  • IOP reduction at 6 months washed out post-DSLT compared with washed out baseline IOP.6 Months post-DSLT